Inhaled corticosteroids in Chronic Obstructive Pulmonary Disease (COPD)

Phase 4

Completed

• Conditions: Smoking-related COPD; Respiratory - Chronic obstructive pulmonary disease

• Registration Number: ACTRN12607000249459
• Lead Sponsor: GlaxoSmithKline

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2007-05-08
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 35

Inclusion Criteria

A physician diagnosis of COPD and evidence of airflow limitation on spirometry.

Exclusion Criteria

Potential participants were interviewed and examined by a respiratory physician and any history suggestive of asthma, i.e. symptoms present in childhood, related atopic disorders, eczema or hay fever, significant day-to-day variability or prominent nocturnal symptoms, or a history of wheeze rather than progressive breathlessness and any previous use of ICS excluded that subject from further participation. Other exclusion criteria included significant uncontrolled co-morbidities such as diabetes, angina or cardiac failure, and other co-existing respiratory disorders, i.e. pulmonary fibrosis, lung cancer and bronchiectasis.

Study & Design

• Study Type: Interventional
• Study Design: Not specified